Lutathera (lutetium Lu 177 dotatate) - Novartis
Retreatment With 177Lu-DOTATATE in Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Multicenter Registry (NANETS 2026) - Oct 7, 2026 - Pres time: Nov 5, 2026; 04:10 PM - 05:25 PM; No abstract available 
Clinical • Neuroendocrine Tumor • Oncology • Solid Tumor
https://www.nanetssymposium.net/day1-program
 
Courtney Porfido, BA
 
Oct 7, 2026
 
Prev Next